A pharma giant is moving past one patent cliff — but another is already looming
Disappointing data highlights Novartis' challenge to build its next generation of blockbuster medicines, following a series of clinical trial setbacks.
Taƙaitaccen labari
Disappointing data highlights Novartis' challenge to build its next generation of blockbuster medicines, following a series of clinical trial setbacks.
Bi sabbin labarai daga amintattun mawallafa tare da taƙaitaccen bayani. Buɗe mahaɗin tushe na asali don cikakken bayani.